ClinicalTrials.gg
Active, not recruitingNCT02452008Updated Nov 6, 2026Results posted

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

A Phase 2 interventional study of Enzalutamide and LY2157299 in Prostate Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Active, not recruiting at 4 sites in United States. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 2, Interventional, and Treatment

How we know

Updated Nov 6, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
57th of 125
60 · median 52
Started
2016
with 8 others
Phase 2
65 of 125
8 open now
Primary completion
2025-12
later than 12 of 37 live
Registered
55th of 125
by date
Lead sponsor
7 of 125
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 57th largest by enrollment, is one of 9 that started in 2016, is one of 65 in phase 2, reaches primary completion later than 12 of the 37 other live ones, and was the 55th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the progression free survival (PFS) of patients with metastatic castration-resistant prostate cancer treated with enzalutamide in combination with LY2157299 (Arm 1) versus enzalutamide alone (Arm 2).

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • metastatic castration-resistant prostate cancer
  • enzalutamide
  • LY2157299
  • TGF-β receptor inhibitor
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have castration-resistant prostate cancer
  • Must have had prior abiraterone treatment
  • of greater than 3 months
  • (ECOG) performance status 0 or 2
  • Age ≥18 years
  • Have
  • Patients acceptance to have a tumor of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator).
  • Ability to take oral medication
  • Patients must have adequate organ and marrow function defined by study-specified laboratory tests
  • Must use acceptable form of while on study
  • Ability to understand and willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Known history or evidence of
  • Prior chemotherapy for disease in castration-resistant prostate cancer
  • Had surgery within 4 weeks prior to the first dose of study drug
  • Had radiation, biological, or other cancer therapy within 2 weeks prior to the first dose of study drug
  • Had hormonal therapy within 2 weeks prior to the first dose of study drug
  • Systemic within 1 weeks prior to the first dose of study drug
  • Had prior enzalutamide, ARN-509, or galeterone therapy
  • Have moderate or severe cardiovascular disease
  • Have a history of a seizure
  • Have uncontrolled intercurrent illness, including but not limited to ongoing or active infection, systematic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric condition that would limit compliance with study requirements
  • Have a history of any disease:inflammatory bowel disease, (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythmatosus (SLE) autoimmune vasculitis (e.g., Wegener's Granulomatosis), central nervous system (CNS) or motor neuropathy considered to be of autoimmune origin (e.g., Guillian-Barre Syndrome, Myasthenia Gravis, Multiple Sclerosis)
  • Have known history of infection with , , or
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Arm 1: Enzalutamide with LY2157299

    Drug: Enzalutamide · Drug: LY2157299

  • Experimental
    Arm 2: Enzalutamide alone

    Drug: Enzalutamide

Interventions

  • 160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.

    Also known as: XTANDI

  • 150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.

    Also known as: TGF-β receptor inhibitor

06

What researchers measure

Primary outcomes

  1. Progression Free Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2) Using RECIST 1.1 Criteria.

    Time frame: 8 years

Secondary outcomes

  1. Number of Participants With (PSA50) Response

    PSA50 response in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299

    Time frame: 4 years

  2. Overall Survival (OS) in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2).

    Time frame: 8 years

  3. Number of Patients Experiencing Treatment-related Toxicities

    Time frame: 8 years

07

Results

Posted Nov 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm 1: Enzalutamide With LY2157299Arm 2: Enzalutamide Alone
Started3723
Completed3723
Not completed00

Outcome measures

PrimaryProgression Free Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2) Using RECIST 1.1 Criteria.
Time frame:
8 years
Reported as:
Median · months
Progression Free Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2) Using RECIST 1.1 Criteria.
monthsArm 1: Enzalutamide With LY2157299Arm 2: Enzalutamide Alone
Progression Free Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2) Using RECIST 1.1 Criteria.5.6 (2.8 to 8.3)7.3 (3.0 to 13.8)
SecondaryNumber of Participants With (PSA50) Response

PSA50 response in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299

Time frame:
4 years
Reported as:
Count of participants · Participants
Number of Participants With (PSA50) Response
ParticipantsArm 1: Enzalutamide With LY2157299Arm 2: Enzalutamide Alone
Number of Participants With (PSA50) Response76
SecondaryOverall Survival (OS) in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2).
Time frame:
8 years
Reported as:
Median · months
Overall Survival (OS) in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2).
monthsArm 1: Enzalutamide With LY2157299Arm 2: Enzalutamide Alone
Overall Survival (OS) in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2).21.6 (16.3 to 36.1)24 (20.9 to 36.7)
SecondaryNumber of Patients Experiencing Treatment-related Toxicities
Time frame:
8 years
Reported as:
Count of participants · Participants
Number of Patients Experiencing Treatment-related Toxicities
ParticipantsArm 1: Enzalutamide With LY2157299Arm 2: Enzalutamide Alone
Number of Patients Experiencing Treatment-related Toxicities2318

Adverse events

Collected over Baseline to End of Treatment approximately 8 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: Enzalutamide With LY215729937/37 (100%)5/37 (13.5%)20/37 (54.1%)
Arm 2: Enzalutamide Alone20/23 (87%)8/23 (34.8%)11/23 (47.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventArm 1: Enzalutamide With LY2157299Arm 2: Enzalutamide Alone
Acute Kidney InjuryRenal and urinary disorders0/372/23
Generalized Muscle WeaknessMusculoskeletal and connective tissue disorders0/372/23
White Blood Cell DecreasedInvestigations0/371/23
SepsisInfections and infestations0/371/23
Treatment Related Secondary MalignancyNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/371/23
FallInjury, poisoning and procedural complications0/371/23
Abdominal PainGastrointestinal disorders1/370/23
FractureInjury, poisoning and procedural complications1/370/23
HypercalcemiaMetabolism and nutrition disorders1/370/23
FatigueGeneral disorders1/370/23
Most frequent other events
Showing 10 of 25
Most frequent other events
EventArm 1: Enzalutamide With LY2157299Arm 2: Enzalutamide Alone
FatigueGeneral disorders20/3711/23
AnorexiaMetabolism and nutrition disorders10/373/23
Back PainMusculoskeletal and connective tissue disorders7/376/23
InsomniaPsychiatric disorders3/376/23
NauseaGastrointestinal disorders9/372/23
AnemiaBlood and lymphatic system disorders7/372/23
Generalized Muscle WeaknessMusculoskeletal and connective tissue disorders2/374/23
DyspneaRespiratory, thoracic and mediastinal disorders6/371/23
Weight LossInvestigations5/371/23
DiarrheaGastrointestinal disorders3/373/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm 1: Enzalutamide With LY2157299Arm 2: Enzalutamide AloneTotal
<=18 years000
Between 18 and 65 years15318
>=65 years222042
Age, Continuous
Age, Continuous(Years)Arm 1: Enzalutamide With LY2157299Arm 2: Enzalutamide AloneTotal
Median68 (53 to 85)72 (57 to 84)69 (53 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Enzalutamide With LY2157299Arm 2: Enzalutamide AloneTotal
Female000
Male372360
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: Enzalutamide With LY2157299Arm 2: Enzalutamide AloneTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American7310
White291847
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)Arm 1: Enzalutamide With LY2157299Arm 2: Enzalutamide AloneTotal
United States372360
08

Study locations

4 sites
09

References and documents

Publications

  • Rodriguez Y, Unno K, Truica MI, Chalmers ZR, Yoo YA, Vatapalli R, Sagar V, Yu J, Lysy B, Hussain M, Han H, Abdulkadir SA. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2022 Jun 6;82(11):2110-2123. doi: 10.1158/0008-5472.CAN-21-3565. PubMed 35405009 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Dec 2025, 115 months.

Results were first posted in Nov 2026, 10 months after primary completion.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's 115 months is above that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2015
First posted
May 22, 2015
StartActual
May 3, 2016
Primary completionActual
Dec 8, 2025
CompletionEst.
Dec 2026
Results first posted
Nov 6, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProgression free survivalFree Survival in patients with metastatic castrationPatients With Metastatic Castration-resistant prostate cancer treated with enzalutamideProstate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) versus enzalutamide aloneVersus Enzalutamide Alone (Arm 2) usingUsing RECIST 1.1 criteriaCriteria.Time frame: 4 years → 8 years
Nov 6, 2026
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedTumor marker kineticsOverall Survival (PSAOS) in patients with metastatic castrationPatients With Metastatic Castration-resistant prostate cancer treated with enzalutamideProstate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) versus enzalutamide aloneVersus Enzalutamide Alone (Arm 2).Time frame: 4 years → 8 years
  • EditedNumber of patients experiencing treatmentPatients Experiencing Treatment-related toxicitiesToxicitiesTime frame: 4 years → 8 years
  • ChangedBefore Overall survival (OS) in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299 (Arm 1) versus enzalutamide alone (Arm 2).Now Number of Participants With (PSA50) ResponseTime frame: 4 years
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProgression free survivalFree Survival in patients with metastatic castrationPatients With Metastatic Castration-resistant prostate cancer treated with enzalutamideProstate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) versus enzalutamide aloneVersus Enzalutamide Alone (Arm 2) usingUsing RECIST 1.1 criteriaCriteria.Time frame: 4 years → 8 years
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedTumor marker kineticsOverall Survival (PSAOS) in patients with metastatic castrationPatients With Metastatic Castration-resistant prostate cancer treated with enzalutamideProstate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) versus enzalutamide aloneVersus Enzalutamide Alone (Arm 2).Time frame: 4 years → 8 years
    • EditedNumber of patients experiencing treatmentPatients Experiencing Treatment-related toxicitiesToxicitiesTime frame: 4 years → 8 years
    • ChangedBefore Overall survival (OS) in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299 (Arm 1) versus enzalutamide alone (Arm 2).Now Number of Participants With (PSA50) ResponseTime frame: 4 years
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02452008
Collaborators
Eli Lilly and Company, National Capital Foundation
Responsible party
Sponsor
First posted
May 22, 2015
Start date
May 3, 2016
Primary completion
Dec 8, 2025
Completion
Dec 2026 (estimated)
Results posted
Nov 6, 2026
Last update
Nov 6, 2026

Study contacts

Channing Paller, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion